Editorial: Strategies in the drug discovery and development for leishmaniasis: immunomodulators, natural products, synthetic compounds, and drug repositioning

Taís Fontoura de Almeida; Edézio Ferreira Cunha-Junior; João Luiz Mendes Wanderley; Juliana da Silva Pacheco; Lucia Helena Pinto-da-Silva; Valter Viana Andrade-Neto; Suzana Passos Chaves

doi:10.3389/fcimb.2024.1384244

Editorial: Strategies in the drug discovery and development for leishmaniasis: immunomodulators, natural products, synthetic compounds, and drug repositioning

Front Cell Infect Microbiol. 2024 Mar 13:14:1384244. doi: 10.3389/fcimb.2024.1384244. eCollection 2024.

Authors

Taís Fontoura de Almeida¹, Edézio Ferreira Cunha-Junior², João Luiz Mendes Wanderley³, Juliana da Silva Pacheco⁴, Lucia Helena Pinto-da-Silva⁵, Valter Viana Andrade-Neto⁶, Suzana Passos Chaves³

Affiliations

¹ Laboratory of Physiopathology, Biosciences Applied to Health Department, Institute of Medical Sciences, Multidisciplinary Center of Federal University of Rio de Janeiro, Macaé, Brazil.
² Laboratory of Immunoparasitology, Institute of Pharmaceutical Sciences, Multidisciplinary Center of Federal University of Rio de Janeiro, Macaé, Brazil.
³ Laboratory of Immunoparasitology, Biosciences Applied to Health Department, Institute of Medical Sciences, Multidisciplinary Center of Federal University of Rio de Janeiro, Macaé, Brazil.
⁴ Drug Discovery Unit, Department of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, United Kingdom.
⁵ Institute of Veterinary, Department of Veterinary Microbiology and Immunology, Seropédica, RJ, Brazil.
⁶ St Michael Hospital, Li ka Shing Knowledge Institute, Toronto, ON, Canada.

No abstract available

Keywords: Leishmania; chemotherapy; flavonoid; immunomodulation; nanoparticles; protozoa; repositioning drugs; treatment.

Publication types

Editorial

MeSH terms

Biological Products* / pharmacology
Biological Products* / therapeutic use
Drug Discovery
Drug Repositioning
Humans
Immunologic Factors / pharmacology
Immunologic Factors / therapeutic use
Leishmaniasis* / drug therapy

Substances

Biological Products
Immunologic Factors

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors are supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and the Fundação de Apoio à Pesquisa do Estado do Rio de Janeiro Carlos Chagas Filho (FAPERJ).